etoricoxib + Other COX-2 inhibitor + nsNSAIDs
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spondylarthropathies; Spondylitis, Ankylosing
Conditions
Spondylarthropathies; Spondylitis, Ankylosing
Trial Timeline
Feb 15, 2011 → Dec 6, 2018
NCT ID
NCT01327638About etoricoxib + Other COX-2 inhibitor + nsNSAIDs
etoricoxib + Other COX-2 inhibitor + nsNSAIDs is a pre-clinical stage product being developed by Organon for Spondylarthropathies; Spondylitis, Ankylosing. The current trial status is completed. This product is registered under clinical trial identifier NCT01327638. Target conditions include Spondylarthropathies; Spondylitis, Ankylosing.
What happened to similar drugs?
2 of 3 similar drugs in Spondylarthropathies; Spondylitis, Ankylosing were approved
Approved (2) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
3
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01327638 | Pre-clinical | Completed |
Competing Products
3 competing products in Spondylarthropathies; Spondylitis, Ankylosing
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Secukinumab | Novartis | Phase 3 | 40 |
| Etanercept | Pfizer | Approved | 43 |
| Methotrexate | Orion Corporation | Approved | 32 |